ClinicalTrials.gg
CompletedNCT06444204Updated Jun 5, 2024

A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)

A Phase 1 interventional study of Rilzabrutinib in Hepatic Function Abnormal and Healthy Volunteers, sponsored by Principia Biopharma, a Sanofi Company. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-05.

Sponsored by Principia Biopharma, a Sanofi Company (part of Sanofi) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2021, 5 years 7 months ago, and no results have been posted to the registry.
  • Registered 3 years 6 months after the study started (first participant enrolled Nov 2020, registered May 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 368 studies in Liver Diseases with a site in United States — 45 open to participants now, 59 under way, 5 of them phase 3. Liver Diseases · United States.

Enrollment
169th of 269
29 · median 48
Started
2020
with 16 others
Phase 1
62 of 368
4 open now
Registered
342nd of 368
by date

Among the 368 studies in Liver Diseases with a site in United States, this one is the 169th largest by enrollment of the 269 interventional ones that give a count, is one of 17 that started in 2020, is one of 62 in phase 1, and was the 342nd registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

45 of the 368 studies in Liver Diseases with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 368 studies in Liver Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a single-dose study to assess the effect of mild or moderate Hepatic Impairment (HI) on the Pharmacokinetics (PK) of rilzabrutinib as well as to evaluate the safety and tolerability of rilzabrutinib in subjects with HI.

03

Conditions studied

  • Hepatic Function Abnormal
  • Healthy Volunteers

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hepatic Impaired Subjects:

    • Non-smoking or light smoker (not exceeding 5 cigarettes per day), adult male or non-pregnant, non-lactating female, 18-75 years of age, inclusive, at screening.
    • Weight ≥ 50 kg, at screening.
  • Healthy Subjects:

    • Non-smoking or light smoker (not exceeding 5 cigarettes per day), healthy, adult males and non-pregnant, non-lactating females, 18-75 years of age, inclusive, at screening.

Subject must be matched for age (within ± 10 years), and sex of the matched subject with hepatic impairment.

--Weight ≥ 50 kg at screening.

Additional inclusion criteria might apply.

Exclusion criteria

Exclusion Criteria:

  • Hepatic Impaired Subjects:

    • Pregnant or lactating female.
    • Uncontrolled treated/untreated hypertension (systolic blood pressure ≥ 160 millimeters of mercury [mmHg] and/or diastolic blood pressure ≥ 105 mmHg), or resting pulse rate \< 45 or > 100 beats per minute (bpm). Measurements may be repeated once in order to determine eligibility.
  • Healthy Subjects

    • Pregnant or lactating female.
    • Uncontrolled treated/untreated hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 105 mmHg), or resting pulse rate \< 45 or > 100 bpm. Measurements may be repeated once in order to determine eligibility.

Additional exclusion criteria might apply.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Rilzabrutinib: Mild Hepatic Impairment

    Subjects with mild Hepatic Impairment (HI)

    Drug: Rilzabrutinib

  • Experimental
    Rilzabrutinib: Moderate Hepatic Impairment

    Subjects with moderate Hepatic Impairment (HI)

    Drug: Rilzabrutinib

  • Experimental
    Rilzabrutinib: Healthy-Matched Control

    Subjects with normal hepatic function

    Drug: Rilzabrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve of total rilzabrutinib in plasma from 0 to t (AUC0-t)

    Time frame: Up to 30 hours after rilzabrutinib dosing

  2. Area under the concentration-time curve of total rilzabrutinib in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)

    Time frame: Up to 30 hours after rilzabrutinib dosing

  3. Percent of AUC0-inf extrapolated total rilzabrutinib in plasma (%AUCextrap )

    Time frame: Up to 30 hours after rilzabrutinib dosing

  4. Maximum measured concentration of total rilzabrutinib in plasma (Cmax)

    Time frame: Up to 30 hours after rilzabrutinib dosing

  5. Time from dosing to maximum measured concentration of total rilzabrutinib in plasma (tmax)

    Time frame: Up to 30 hours after rilzabrutinib dosing

  6. Terminal Half-Life of total rilzabrutinib in Plasma (t1/2)

    Time frame: Up to 30 hours after rilzabrutinib dosing

  7. Elimination Rate Constant of total rilzabrutinib (Kel)

    Time frame: Up to 30 hours after rilzabrutinib dosing

  8. Apparent Total Clearance of rilzabrutinib in the plasma after extra-vascular administration (CL/F)

    Time frame: Up to 30 hours after rilzabrutinib dosing

  9. Apparent Volume of Distribution during the Terminal elimination phase after extravascular administration (Vz/F)

    Time frame: Up to 30 hours after rilzabrutinib dosing

  10. Fraction of unbound drug ( rilzabrutinib) expressed as percent (%fu)

    Time frame: Up to 24 hours after rilzabrutinib dosing

  11. Number of Adverse Events (AE) / Serious Adverse Events (SAE)

    Time frame: From date of signed ICF, up to 9 days after rilzabrutinib dosing

  12. Incidence of potentially clinically significant laboratory test, vital signs, and electrocardiogram (ECGs) abnormalities

    Time frame: Up to 30 hours after rilzabrutinib dosing

Secondary outcomes

  1. Area under the concentration-time curve of rilzabrutinib metabolites in plasma from 0 to t (AUC0-t)

    Time frame: Up to 24 hours after rilzabrutinib dosing

  2. Area under the concentration-time curve of rilzabrutinib metabolites in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf)

    Time frame: Up to 24 hours after rilzabrutinib dosing

  3. Percent of AUC0-inf extrapolated rilzabrutinib metabolites in plasma (%AUCextrap)

    Time frame: Up to 24 hours after rilzabrutinib dosing

  4. Maximum measured concentration of rilzabrutinib metabolites in plasma (Cmax)

    Time frame: Up to 24 hours after rilzabrutinib dosing

  5. Time from dosing to maximum measured concentration of rilzabrutinib metabolites in plasma (tmax)

    Time frame: Up to 24 hours after rilzabrutinib dosing

  6. Terminal Half-Life of rilzabrutinib metabolites in Plasma (t1/2)

    Time frame: Up to 24 hours after rilzabrutinib dosing

  7. Elimination Rate Constant of rilzabrutinib metabolites (Kel)

    Time frame: Up to 24 hours after rilzabrutinib dosing

  8. Metabolite-to-parent ratio (MRAUC)

    MRAUC is Based on AUC0-t, corrected for Molecular weights (MW). MRAUC = (AUC0-t,M/AUC0-t,P) x (MW,P/MW,M) where M was metabolite and P was parent.

    Time frame: Up to 24 hours after rilzabrutinib dosing

  9. Metabolite-to-parent ratio (MRCmax)

    MRCmax is based on Cmax, corrected for MW. MRCmax = (Cmax,M/ Cmax,P) x (MW,P/MW,M) where M was metabolite and P was parent.

    Time frame: Up to 24 hours after rilzabrutinib dosing

07

Study locations

2 sites
  • Investigational Site Number: 0002
    Miami, Florida 33014, United States
  • Investigational Site Number: 0001
    Orlando, Florida 32809, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Mar 2021, 4 months.

Of 48 industry-sponsored phase 1 interventional studies under Liver Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 4 months is below that.

Counting every sponsor, half of 53 studies reached it within 14 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2024
First posted
Jun 5, 2024
StartActual
Nov 2, 2020
Primary completionActual
Mar 23, 2021
CompletionActual
Mar 23, 2021
Last update
Jun 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06444204
Responsible party
Sponsor
First posted
Jun 5, 2024
Start date
Nov 2, 2020
Primary completion
Mar 23, 2021
Completion
Mar 23, 2021
Last update
Jun 5, 2024

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilzabrutinib

Start the discussion